Infratil (ASX:IFT, NZE:IFT) said there was potential for divestments for a further NZ$1 billion or more over the medium term as it assesses the growth outlook and scale opportunities of its existing assets, according to filings with both the Australian and New Zealand bourses.
A sale process is currently underway for its stake in Australian medical imaging provider Qscan.
It also plans to lodge a product disclosure statement for an inaugural offering of capital bonds on Tuesday.
Its shares fell over 6% on the New Zealand bourse in recent trading on Tuesday and over 5% on the Australian bourse.